The progression of the inflammation in established collagen‐induced arthritis can be altered by treatments with immunological or pharmacological agents which inhibit T cell activities
- 1 June 1988
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 18 (6) , 881-888
- https://doi.org/10.1002/eji.1830180608
Abstract
Alterations in the progression of the inflammatory disease in mice with established collagen-induced arthritis (CIA) by in vivo treatments with either anti-T cell antibodies or an immunosuppressive drug, whose main targets of action are T cells, were studied. It was demonstrated that the in vivo administration of either monoclonal anti-L3T4, anti-Ly-2 or the combination of anti-L3T4 and anti-Ly-2 failed to modify the inflammatory disease after the arthritis had been initiated. Nevertheless, the progression of disease was decreased by treatments with rabbit anti-mouse lymphocyte sera (ALS) in mice with established CIA. While there was a substantial reduction in the proliferative responses to the T cell mitogen concanavalin A (Con A) in these ALS-treated mice, proliferation to a B cell mitogen, lipopolysaccharide, was unaffected. Furthermore, treatments with anti-Thy-1.2 monoclonal antibody (mAb) by itself did not alter the progression of the ongoing inflammatory disease, but combined treatments with both anti-Thy-1.2 and anti-L3T4 mAb prevented the further advancement of the arthritic disease. Although mice receiving either anti-Thy-1.2 alone or both anti-Thy-1.2 and anti-L3T4 exhibited complete absence of Thy-1+ cells within their inguinal lymph nodes, the proliferative responses to Con A by LN cells from mice treated with the combination of anti-Thy-1.2 and anti-L3T4 were drastically reduced compared to the responses of either the anti-Thy-1.2 or anti-13T4-treated groups. Finally, daily treatments with cyclosporin A, an immunosuppressive drug which preferentially acts on T cells, were also effective in modifying the clinical course of the arthritic disease in mice with established CIA. These results suggest that immunocompetent cells which express the Thy-1 surface marker, most likely Thy-1+ T cells, may play a role in maintaining and perpetuating the inflammatory disease of established CIA.This publication has 41 references indexed in Scilit:
- Tolerance to rat monoclonal antibodies. Implications for serotherapy.The Journal of Experimental Medicine, 1986
- Effects of cyclosporin on collagen induced arthritis in mice.Annals of the Rheumatic Diseases, 1986
- Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4.The Journal of Experimental Medicine, 1985
- Therapy with monoclonal antibodies by elimination of T-cell subsets in vivoNature, 1984
- DEVELOPMENT OF SUPPRESSOR T CELLS BY ANTILYMPHOCYTE SERUM TREATMENT IN MICETransplantation, 1982
- Nature and specificity of the immune response to collagen in type II collagen-induced arthritis in mice.Journal of Clinical Investigation, 1982
- Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates.The Journal of Experimental Medicine, 1981
- Immunisation against heterologous type II collagen induces arthritis in miceNature, 1980
- Genetic control of the immune response to collagen. II. Antibody responses produced in fetal liver restored radiation chimeras and thymus reconstituted F1 hybrid nude mice.The Journal of Experimental Medicine, 1979
- THE USE OF SPECIFIC "LYMPHOCYTE" ANTISERA TO INHIBIT HYPERSENSITIVE REACTIONS OF THE "DELAYED" TYPEThe Journal of Experimental Medicine, 1961